ਬਲੱਡ ਕੈਂਸਰ (AML leukaemia)
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
ਕਿੱਥੇ ਜਾਣਾ ਹੈ
ਭਾਰਤ ਵਿੱਚ 11 ਹਸਪਤਾਲ ਇਸ ਟਰਾਇਲ ਲਈ ਮਰੀਜ਼ਾਂ ਨੂੰ ਲੈ ਰਹੇ ਹਨ।
ਰਜਿਸਟਰੀ ਸਮਰੀ (ਤਕਨੀਕੀ)
Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for participants who are unable to undergo standard induction therapy, the current standard of care. This study will assess the change in disease activity and adverse events in adult participants with acute myeloid leukemia (AML) being treated with of the combination of azacitidine and venetoclax, in India. The combination of azacitidine and venetoclax is being evaluated in the treatment of acute myeloid leukemia (AML). Participants will receive azacitidine with increasing d…
ਸਪਾਂਸਰ: AbbVie
ClinicalTrials.gov 'ਤੇ NCT07044687
ਰਜਿਸਟਰੀ 'ਤੇ ਆਖਰੀ ਵਾਰ 11 Sep 2026 ਨੂੰ ਅਪਡੇਟ ਕੀਤਾ ਗਿਆ · ਸਾਡੇ ਵੱਲੋਂ 20 Oct 2026 ਨੂੰ ਪੜ੍ਹਿਆ ਗਿਆ